Now showing items 4-7 of 7

    • Grey matter atrophy in prodromal stage of dementia with Lewy bodies and Alzheimer’s disease 

      Blanc, Frederic; Colloby, Sean J; Cretin, Benjamin; de Sousa, Paulo Loureiro; Demuynck, Catherine; O'Brien, John Tiernan; Martin-Hunyadi, Catherine et al. (BioMed Central, 2016-07-20)
      ${\bf Introduction:}$ Little is known about the patterns of brain atrophy inprodromal Dementia with Lewy bodies (pro-DLB). ${\bf Methods:}$ In this study, we used SPM8-DARTEL to measure gray matter (GM) volume and ...
    • Lewy bodies and neuronal loss in subcortical areas and disability in non-demented older people: a population based neuropathological cohort study 

      Byford, M; Brayne, Carol Elspeth; McKeith, Ian; Chatfield, Mark; Ince, Paul G; Matthews, Fiona E; MRC-CFAS, (2009-06-15)
      Abstract Background Functional disability, the loss of ability to carry out daily tasks unaided, is a major adverse outcome more common with increasing age. The potential contribution of neuropathological changes in ...
    • Non-pharmacological interventions for Lewy body dementia: a systematic review. 

      Connors, Michael H; Quinto, Lena; McKeith, Ian; Brodaty, Henry; Allan, Louise; Bamford, Claire; Thomas, Alan et al. (Cambridge University Press, 2017-11-16)
      Lewy body dementia (consisting of dementia with Lewy bodies and Parkinson’s disease dementia) is a common neurodegenerative disease characterised by visual hallucinations, fluctuating attention, motor disturbances, falls, ...
    • Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis 

      Stinton, Chris; McKeith, Ian; Taylor, John-Paul; Lafortune, Louise; Mioshi, Eneida; Mak, Elijah; Cambridge, Victoria et al. (American Psychiatric Association, 2015-06-18)
      Objective: The authors examined research on effects, costs, and patient and caregiver views of pharmacological management strategies for Lewy body dementia. Method: Studies were identified through bibliographic databases, ...